DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1802)

36 Biopharma Reports

  • hepatitis c virus
The market opportunity for hepatitis C virus (HCV) is marked by a large...
The market opportunity for hepatitis C virus (HCV) is marked by a large prevalent population and high unmet medical need due to the suboptimal tolerability and efficacy of early, interferon-based H......
In January 2014, the European Medicines Agency granted marketing authorization...
In January 2014, the European Medicines Agency granted marketing authorization to the first nucleotide polymerase inhibitor, sofosbuvir (Gilead’s Sovaldi), for the treatment of hepatitis C virus (H......
The primary goal of hepatitis C virus (HCV) treatment is to completely eliminate...
The primary goal of hepatitis C virus (HCV) treatment is to completely eliminate the virus from the patient’s body and thereby reduce or halt the progression of liver fibrosis, preventing further c......
1 - 20 of 36